Back    Zoom +    Zoom -
CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products
Recommend
35
Positive
73
Negative
31
The Chinese government has directed some state-owned pharmaceutical companies to explore ways to reduce dependence on U.S.-made drugs and raw materials, Bloomberg cited sources. This move comes as Beijing prepares for potential decoupling risks that could threaten medical supply chains.

China’s National Medical Products Administration (NMPA) conveyed this directive to executives of state-owned pharmaceutical firms earlier this year, report told. The instruction focuses on assessing the feasibility of substituting U.S.-manufactured medical products.

Related NewsNomura Downgrades AKESO (09926.HK) to Neutral, Elevates TP to $99.66
The products targeted for substitution cover a wide range, including ingredients and supplies used to make drugs, as well as lab equipment and testing reagents. These could be sourced domestically or imported from countries such as Japan.
AAStocks Financial News